Measurements with polarographic needle probes in fibromyalgic muscles (mm. erectores spinae) revealed an elevated mean tissue-pO2. The total mean tissue-pO2 in the patient group was significantly higher than that in the control group. Greater pathological tension in fibromyalgic muscles increases the mean tissue-pO2. The distribution of local tissue-pO2 values was normal; there was no evidence of small hypoxic areas in the muscle. The elevated tissue-pO2 in fibromyalgic muscles could either be explained by an increase in local blood flow or by disturbance of oxygen-utilization of the muscle cells. The mean tissue-pO2 in patients treated with NSAD was lower than in patients without this treatment. Myogelosises (i.e., circumscript tautness in muscles, that, contrary to fibromyalgic muscles, do not relax under general anesthesia) showed low tissue-pO2 values and even hypoxia in the core. In myogelosises, pain could be hypoxic in nature. However, in fibromyalgic muscles no evidence for hypoxia or hypoxia-related pain could be found.

Download full-text PDF

Source

Publication Analysis

Top Keywords

fibromyalgic muscles
20
elevated tissue-po2
8
tissue-po2 values
8
tissue-po2
7
muscles
6
fibromyalgic
5
[tissue po2
4
po2 measurement
4
measurement taut
4
taut musculature
4

Similar Publications

Chronic pain as a presenting feature of dysferlinopathy.

Neuromuscul Disord

December 2024

Service de Neuromyologie, Centre de référence des maladies neuromusculaires Nord/Est/Ile de France Institut de Myologie, Sorbonne Université, APHP, Paris, France. Electronic address:

Dysferlinopathies, caused by mutations in the dysferlin gene (DYSF) encoding the dysferlin protein, are a clinically heterogeneous group of autosomal recessive muscular dystrophies whose phenotypic spectrum is still evolving. Here we described a patient reporting diffuse muscular pain non related to physical exercise, mimicking fibromyalgic syndrome. Electroneuromyography was normal.

View Article and Find Full Text PDF

Ultramicronized Palmitoylethanolamide (um-PEA) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients.

CNS Neurol Disord Drug Targets

August 2020

Department of Surgery, Dentistry, Maternal and Infant Sciences, Pain Therapy Centre, Verona University Hospital, Policlinico GB Rossi, Verona, Italy.

Background: Fibromyalgia syndrome is a chronic multifaceted disease characterized by widespread pain, muscle stiffness, fatigue, unrefreshing sleep and cognitive disorders. To date, no medication has been shown to significantly improve pain, associated symptoms and Quality of Life in fibromyalgic patients.

Methods: In this retrospective observational study, we analyzed data regarding 407 patients with diagnosis of fibromyalgia syndrome who between 2013 and 2016 have been prescribed orally ultramicronized palmitoylethanolamide tablets (Normast® Epitech Group SpA, Saccolongo, Italy) regardless of the concomitant pharmacological therapy (add-on treatment).

View Article and Find Full Text PDF

Background: Chronic fatigue syndrome (CFS) or Myalgic Encephalomyelitis (ME) is characterized by neuro-psychiatric (e.g. depression, irritability, sleep disorders, autonomic symptoms and neurocognitive defects) and physio-somatic (fatigue, a flu-like malaise, hyperalgesia, irritable bowel, muscle pain and tension) symptoms.

View Article and Find Full Text PDF

Unlabelled: Macrophagic myofasciitis (MMF) is a specific histological lesion assessing the persistence of vaccine-derived aluminum oxyhydroxide in muscle tissue, at a site of previous immunization. Long-lasting MMF is usually detected in patients with arthromyalgias, chronic fatigue, and stereotyped cognitive dysfunction. MMF diagnosis requires muscle biopsy, an invasive procedure not suitable for the routine investigation of all patients with musculoskeletal pain.

View Article and Find Full Text PDF

Objective: To identify muscle physiologic properties that may contribute to postexertional fatigue and malaise in women with fibromyalgia (FM).

Methods: Healthy postmenopausal women with (n = 11) and without (n = 11) FM, ages 51-70 years, participated in this study. Physical characteristics and responses to self-reported questionnaires were evaluated.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!